SB
Therapeutic Areas
Bausch Health Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Xifaxan (rifaximin) | Hepatic Encephalopathy | Approved |
| Relistor (methylnaltrexone) | Opioid-Induced Constipation | Approved |
| Trulance (plecanatide) | Chronic Idiopathic Constipation & IBS-C | Approved |
| Amitiza (lubiprostone) | CIC, IBS-C, Opioid-Induced Constipation | Approved |
| Solta Medical Portfolio | Aesthetic Treatments | Commercial |
| Brovana (arformoterol tartrate) | COPD | Approved |
| Lumify (brimonidine tartrate) | Ocular Redness | OTC |
| Lotemax (loteprednol etabonate) | Ophthalmic Inflammation | Approved |
Leadership Team at Bausch Health
TJ
Thomas J. Appio
Chief Executive Officer
SE
Sam Eldessouky
Executive Vice President & Chief Financial Officer
CA
Christina Ackermann
Executive Vice President, General Counsel & Chief Compliance Officer
R(
Robert (Bob) Spurr
President, Bausch Health U.S. & Global R&D
TM
Tricia M. Sanvito
Executive Vice President, Human Resources
JC
Joseph C. Papa
Chairman of the Board
RU
Richard U. DeSchutter
Director
JE
John E. Paulson
Director
AD
Arthur D. Levitan
Director
SD
Steven D. Miller
Director